Ultime notizie per Sorrento Therapeutics (OTC:SRNE) Azioni

Sorrento Therapeutics

Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

SORRENTO THERAPEUTICS INC by Sorrento Therapeutics, Inc.

Sorrento Therapeutics Inc

Healthcare bankruptcies slow after peaking in 2023: report

AHPIQ

AKUMQ

ATHXQ

CANOQ

DMTKQ

GMDAQ

HGENQ

NVTAQ

RADCQ

SDCCQ

SRNE

VRAYQ

Cantor Fitzgerald

HC Wainwright & Co.

Comments

Sorrento Therapeutics

Notizie

Ultime notizie per Sorrento Therapeutics (OTC:SRNE) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO